Development of Pharmacotherapies for the Treatment of Sarcopenia
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Sarcopenia, the associated loss of skeletal muscle mass and strength and impaired physical function seen with aging, is a growing, global public health challenge in need of accepted, proven treatments that address the needs of a broad range of older adults. While exercise, primarily resistance training, and increased dietary protein have been shown to delay and even reverse losses in muscle mass, strength and physical function seen with aging, proven treatments that are accessible globally, cost effective and sustainable by patients are needed. While no drug has yet demonstrated the substantial safety and clinical value needed to be the first pharmacological therapy registered for muscle wasting or sarcopenia, the field is active. Several approaches to treating the muscle loss and subsequent functional decline are being studied in a variety of patient populations across every continent. We provide a review of the leading programs and approaches and available findings from recent studies. In addition, we briefly discuss several related issues needed to facilitate the development of a safe and efficacious pharmacotherapeutic that could be used as part of a treatment plan for older men and women with sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gait speed and survival in older adults.
Studenski, S. (2011) · JAMA · doi:10.1001/jama.2010.1923 · Cited by 4,558 · cited 1×
“…body of epidemiological and intervention-based literature demonstrating a strong association between decreased gait speed (≥ 0.1 m/s) and future adverse physical, psychological and cognitive status, and health outcomes including falls, hospitalizations, mobility disability and death (89-91).”
InfluentialSarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 1×
“Proposed in most consensus statements, grip strength is easy to administer, perform and interpret, does not require motor learning and is relatively inexpensive (32-35, 37, 76).”
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256 · cited 1×
“Gait speeds of 0.8 m/s and 1.0 m/s over four meters have been recommended to identify older adults at increased risk of functional decline, mobility impairment and adverse health events (32, 34-36, 54, 58).”
InfluentialSelf-citationGoodpaster, B. H., Park, S. W., Harris, T. B., Kritchevsky, S. B., Nevitt, M., Schwartz, A. V., Simonsick, E. M., Tylavsky, F. A., Visser, M., Newman, A. B., et al. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.10.1059 · Cited by 3,083 · cited 1×
“Skeletal muscle weakness is commonly seen with aging and a reduction in skeletal muscle mass, and correlates with mobility disability and other adverse health outcomes (12, 36, 92).”
Guralnik, J. M., Ferrucci, L., Pieper, C. F., Leveille, S. G., Markides, K. S., Ostir, G. V., Studenski, S., Berkman, L. F., & Wallace, R. B. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.4.m221 · Cited by 2,898
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545 · cited 4×
“This use allows prevalence estimates to be established while considering racial, ethnic and geographical differences (36, 39-44).”
InfluentialSarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 1×
“In 1989, Irwin Rosenberg introduced the term “sarcopenia”, to describe the age-associated loss of skeletal muscle mass (31).”
Abellan Van Kan, G., Rolland, Y., Andrieu, S., Bauer, J., Beauchet, O., Bonnefoy, M., Cesari, M., Donini, L. M., Gillette-Guyonnet, S., Inzitari, M., et al. (2009) · The Journal of nutrition, health and aging · doi:10.1007/s12603-009-0246-z · Cited by 2,003
Cruz-Jentoft, A. J., Landi, F., Schneider, S. M., Zuniga, C., Arai, H., Boirie, Y., Chen, L.-K., Fielding, R. A., Martin, F. C., Michel, J.-P., et al. (2014) · Age and Ageing · doi:10.1093/ageing/afu115 · Cited by 1,963
Muscaritoli, M., Anker, S. D., Argilés, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., et al. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.12.004 · Cited by 1,732 · cited 2×
“, isometric handgrip strength) and usual gait speed, with a focus on the individual’s quality of life and risk of adverse health events (32-36).”
High-Intensity Strength Training in Nonagenarians: Effects on Skeletal Muscle
Fiatarone, M. A. (1990) · JAMA · doi:10.1001/jama.1990.03440220053029 · Cited by 1,593
The healthcare costs of sarcopenia in the United States
Janssen, I., Shepard, D. S., Katzmarzyk, P. T., & Roubenoff, R. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52014.x · Cited by 1,546
Self-citationAging of skeletal muscle: a 12-yr longitudinal study
Frontera, W. R., Hughes, V. A., Fielding, R. A., Fiatarone, M. A., Evans, W. J., & Roubenoff, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1321 · Cited by 1,443
Self-citationPahor, M., Guralnik, J. M., Ambrosius, W. T., Blair, S., Bonds, D. E., Church, T. S., Espeland, M. A., Fielding, R. A., Gill, T. M., Groessl, E. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.5616 · Cited by 1,427 · cited 1×
“There is a substantial body of literature demonstrating the benefits of exercise, primarily resistance training, and physical activity on muscle mass, strength and function in older adults of various levels of baseline physical function (10-14).”
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Physical performance measures in the clinical setting
Studenski, S., Perera, S., Wallace, D., Chandler, J. M., Duncan, P. W., Rooney, E., Fox, M., & Guralnik, J. M. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51104.x · Cited by 1,218 · cited 4×
“…test-retest reliability (73); construct validity (79, 80); predictive validity for mortality (79, 81), incident disability (77, 82), institutionalization and hospitalization (73, 79), functional decline after hospital discharge (83); and sensitivity to clinically important change (72, 80, 84).”
InfluentialShort physical performance battery and all-cause mortality: systematic review and meta-analysis
Pavasini, R., Guralnik, J., Brown, J. C., di Bari, M., Cesari, M., Landi, F., Vaes, B., Legrand, D., Verghese, J., Wang, C., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0763-7 · Cited by 911 · cited 1×
“Muscle strength, chair rise ability and gait speed assessment can predict mobility limitation (75-78) and their inclusion could move the field closer to universally accepted assessments of a person’s physical capability – the ultimate clinical goal.”
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
III, L. J. M., Khosla, S., Crowson, C. S., O'Connor, M. K., O'Fallon, W. M., & Riggs, B. L. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb04719.x · Cited by 598
Signaling pathways controlling skeletal muscle mass
Egerman, M. A., & Glass, D. J. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.857291 · Cited by 555
Grip Strength Cutpoints for the Identification of Clinically Relevant Weakness
Alley, D. E., Shardell, M. D., Peters, K. W., McLean, R. R., Dam, T.-T. L., Kenny, A. M., Fragala, M. S., Harris, T. B., Kiel, D. P., Guralnik, J. M., et al. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu011 · Cited by 535 · cited 2×
“Lower muscle strength, including when assessed by handgrip, is associated with higher risks for falling, chronic disease, impaired mobility and disability (57, 75, 93).”
GDF11 increases with age and inhibits skeletal muscle regeneration
Egerman, M. A., Cadena, S. M., Gilbert, J. A., Meyer, A., Nelson, H. N., Swalley, S. E., Mallozzi, C., Jacobi, C., Jennings, L. L., Clay, I., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.010 · Cited by 527 · cited 1×
“Several members of the transforming growth factor beta (TGF-β) superfamily of secreted proteins, including myostatin (growth and differentiation factor 8; GDF8), activin A, and GDF11, negatively regulate skeletal muscle mass in animals and humans throughout the lifecycle (103-106).”
Regulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501
Mijnarends, D. M., Meijers, J. M. M., Halfens, R. J. G., ter Borg, S., Luiking, Y. C., Verlaan, S., Schoberer, D., Cruz Jentoft, A. J., van Loon, L. J. C., & Schols, J. M. G. A. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.10.009 · Cited by 475
Cawthon, P. M., Peters, K. W., Shardell, M. D., McLean, R. R., Dam, T.-T. L., Kenny, A. M., Fragala, M. S., Harris, T. B., Kiel, D. P., Guralnik, J. M., et al. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu023 · Cited by 388
Liao, C.-D., Tsauo, J.-Y., Wu, Y.-T., Cheng, C.-P., Chen, H.-C., Huang, Y.-C., Chen, H.-C., & Liou, T.-H. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.143594 · Cited by 317 · cited 1×
“The topics of exercise and nutrition for improved health and function and as contributors to and potential treatment for sarcopenia in older adults have been reviewed recently (3, 25-27).”
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314 · cited 1×
“Advances in understanding of the biology associated with aging, muscle wasting and sarcopenia provide potential targets for drug discovery and are being pursued by the pharmaceutical and biotech industries and academia (28-30).”
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306 · cited 4×
“Postpartum blockade of myostatin activity in animals and humans by either direct action on the ligand (111-115) or receptor antagonism (108, 109, 116, 117) is associated with varying degrees of muscle hypertrophy, and less frequently with clinically meaningful improvement in physical function (117).”
InfluentialDevelopment of selective androgen receptor modulators (SARMs)
Narayanan, R., Coss, C. C., & Dalton, J. T. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.013 · Cited by 251 · cited 2×
“SARMs have demonstrated efficacy in recovery of skeletal muscle in several preclinical models of muscle wasting, including corticosteroids and hypogonadism (99, 100).”
Rooks, D., Praestgaard, J., Hariry, S., Laurent, D., Petricoul, O., Perry, R. G., Lach‐Trifilieff, E., & Roubenoff, R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14927 · Cited by 244
Self-citationProtein Requirements and Recommendations for Older People: A Review
Nowson, C., & O'Connell, S. (2015) · Nutrients · doi:10.3390/nu7085311 · Cited by 243 · cited 1×
“Similarly, data showing the efficacy of increased dietary protein and other nutrients to support healthy aging and the maintenance of physical function have led to revised dietary recommendations for protein and other nutrients in older people (18-20).”
Pharmacologic Options for the Treatment of Sarcopenia
Morley, J. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0022-5 · Cited by 225 · cited 1×
“These approaches include the potential expanded use of available drugs registered for other conditions (3, 97, 98), and to a greater extent the development of new molecular entities (Table 2).”
Papanicolaou, D. A., Ather, S. N., Zhu, H., Zhou, Y., Lutkiewicz, J., Scott, B. B., & Chandler, J. (2013) · The Journal of nutrition, health and aging · doi:10.1007/s12603-013-0335-x · Cited by 196 · cited 1×
“6 kg of appendicular lean body mass over placebo at 3- and 6-months, but did not improve muscle strength or physical performance (assessed by the SPPB, stair climb test and gait speed) compared to placebo (101).”
Activin A more prominently regulates muscle mass in primates than does GDF8
Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185 · cited 2×
“Activin A, another ligand that signals through the ActRII, has recently been proposed to have a greater effect on regulating muscle mass in primates than myostatin (113).”
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707925114 · Cited by 142
Magnitude and patterns of decline in health and function in 1 year affect subsequent 5-year survival
Perera, S., Studenski, S., Chandler, J. M., & Guralnik, J. M. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.7.894 · Cited by 134 · cited 1×
“…on SPPB performance is available, documenting test-retest reliability (73); construct validity (79, 80); predictive validity for mortality (79, 81), incident disability (77, 82), institutionalization and hospitalization (73, 79), functional decline after hospital discharge (83); and…”
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J. A., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H. A., Boers, M., Brandi, M. L., Bruyère, O., et al. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0517-y · Cited by 112
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88
Self-citationEffects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes
Garito, T., Zakaria, M., Papanicolaou, D. A., Li, Y., Pinot, P., Petricoul, O., Laurent, D., Rooks, D., Rondon, J. C., & Roubenoff, R. (2018) · Clinical Endocrinology · doi:10.1111/cen.13601 · Cited by 31 · cited 2×
“The mechanism of action of bimagrumab results in suppression of FSH secretion in women that is reversible with drug discontinuation (130).”
Self-citation
Cited by
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070
Fang, E. F., Xie, C., Schenkel, J. A., Wu, C., Long, Q., Cui, H., Aman, Y., Frank, J., Liao, J., Zou, H., et al. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101174 · Cited by 675
Sarcopenia: A Contemporary Health Problem among Older Adult Populations
Papadopoulou, S. (2020) · Nutrients · doi:10.3390/nu12051293 · Cited by 588
Egan, B., & Sharples, A. P. (2023) · Physiological Reviews · doi:10.1152/physrev.00054.2021 · Cited by 278
Rooks, D., Swan, T., Goswami, B., Filosa, L. A., Bunte, O., Panchaud, N., Coleman, L. A., Miller, R. R., Garcia Garayoa, E., Praestgaard, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20836 · Cited by 177
Self-citation
Metadata
- Authors
- Rooks, D., & Roubenoff, R.
- Venue
- The Journal of Frailty & Aging
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 8
- Issue
- 3
- Pages
- 120-130
- ISSN
- 2260-1341 (ISSN-L)
- OpenAlex
- W2941076520
- Cited by
- 46
- References
- 39
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.